-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ In vitro lentiviral gene therapy presents positive test results, striving to free patients from the burden of chronic treatmentYimai Meng broke the news in November 2021 29th/eMedClub News/--Nykode Therapeutics recently announced that it has reached a cooperation agreement with Regeneron on the development of cancer and infectious disease vaccines
.
According to the terms of this cooperation, Nykode Therapeutics will be responsible for the production and characterization of the vaccine, as well as the product supply before the end of the phase 1 trial
.
Regeneron will be responsible for antigen identification, preclinical and clinical development and manufacturing, and commercialization
.
The agreement includes five different projects, three in the field of cancer and two in the field of infectious diseases
.
These vaccines will combine Regeneron's unique antigen selection expertise, proprietary VelociSuite technology and Nykode Therapeutics' modular vaccine platform
.
Nykode Therapeutics Nykode Therapeutics is a leading clinical stage biopharmaceutical company
.
Nykode Therapeutics is committed to discovering and developing vaccines and new immunotherapies for the treatment of cancer and infectious diseases
.
The core of Nykode Therapeutics' proprietary modular Vaccibody technology is to induce rapid, strong and lasting specific immune responses by targeting antigens to antigen-presenting cells
.
▲ Image source: Nykode Therapeutics official website The Vaccibody molecule consists of three functional modules: a targeting module that binds to the surface receptors of antigen presenting cells, a dimerization module, and an antigen module derived from pathogenic factors
.
The genes of each module are genetically related and encode a new type of fusion protein called the Vaccibody protein
.
The platform can be used to encode a series of different targeting modules and antigen modules to provide fuel for a variety of new products
.
The selected targeting module determines the delivery of the antigen to a specific subpopulation of APC or cell type, which ultimately affects the kinetics and immune response profile
.
So far, clinical Vaccibody vaccines have used a needleless jet syringe to deliver plasmids as DNA plasmids to muscle cells
.
Inside the cell, the DNA plasmid provides information to produce the Vaccibody protein in the same way that the cell produces other human proteins
.
Then the newly encoded Vaccibody protein is secreted from the cell and targets and recruits APC
.
Depending on the selection of the targeting module, different APCs subgroups will be targeted, which means that the immune response may be biased towards body fluids (antibodies) or cells (T cells) or their variants (CD8/CD4, Th1/Th2/Th17/ Treg)
.
▲ Mechanism of action of the Vaccibody platform (picture source: Nykode Therapeutics official website) Off-the-shelf cancer and infectious disease vaccines provide a fast, scalable and attractive method for cancer treatment
.
This vaccine targets shared antigens that are found in pathogens or expressed by tumors in a large population of patients
.
Nykode has accumulated rich experience in ready-made vaccines, including its infectious disease plan and the VB10.
16 clinical plan for HPV16-driven cancer types
.
In order to expand the clinical pipeline, Nykode will focus part of its research efforts on identifying shared cancer antigens and developing other off-the-shelf vaccines with future potential such as cancer, infectious diseases, and autoimmune diseases
.
Nykode Therapeutics' pioneering vaccine: ➤ VB10.
16VB10.
16 is a therapeutic vaccine for the treatment of malignant tumors induced by human papillomavirus 16
.
It is currently in a phase 2 trial for the treatment of cervical cancer
.
➤ VB10.
NEO cancer neoantigen vaccine VB10.
NEO is one of Nykode's main product candidates
.
It is currently in a Phase 1b trial for the treatment of locally advanced and metastatic tumors and a Phase 1/2a trial for the treatment of melanoma, lung cancer, head and neck cancer, kidney cancer and bladder cancer
.
➤ COVID-19 vaccine In 2021, Nykode launched two phase 1/2 trials of next-generation COVID-19 vaccine candidates
.
Michael Engsig, CEO of Nykode Therapeutics, said: "We are very pleased to reach this groundbreaking agreement with Regeneron, which may accelerate the expansion of our product line and take full advantage of our uniqueness in multiple large and commercially important disease areas.
The modular vaccine technology platform
.
This agreement further validates Nykode Therapeutics’s position as a leading next-generation immunotherapy platform company
.
We are excited about the choice of options and their therapeutic potential in cancer, as well as the potential for prevention and treatment of infectious diseases
.
"RegeneronRegeneron is a leading biotechnology company that invents and researches potential new drugs for a variety of serious diseases, including retinal eye disease, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases
.
Regeneron is working through it.
Proprietary VelociSuite technology accelerates and improves the traditional drug development process
.
▲ Image source: Regeneron official website ➤ VelociGeneVelociGene can quickly, automatically and large-scale manipulate mouse DNA, with almost no restrictions on the size and complexity of modifications
.
This makes it possible to validate therapeutic targets The speed and ability to point and create animal models of human diseases has reached unprecedented speed and ability
.
➤ VelociMouseVelociMouse is a breakthrough technology that can directly generate transgenic mice directly from modified embryonic stem cells, thereby avoiding the need for multiple generations of reproduction
.
this technology greatly reduces engineering time transgenic mice, while reducing costs, improving the accuracy
.
➤ VelocImmuneVelocImmune is a unique technology to produce fully human monoclonal antibodies
.
VelocImmune from immunized mice and efficient direct, directly create A large number of optimized antibody drug candidates
.
This method overcomes the limitations of traditional platforms by quickly creating fully human antibodies that are tightly bound to the therapeutic target, and avoiding potential immunity that may occur in patients receiving antibodies containing non-human components Response
.
➤ VelociMabVelociMab is a set of technologies that allows us to enter clinical research from identifying therapeutic antibodies at an unprecedented speed
.
VelociMab can perform high-throughput screening of potential therapeutic antibodies and quickly generate recombinant human antibody cell lines
.
Gavin Thurston, Senior Vice President of Oncology Research at Regeneron, said: "Nykode Therapeutics' platform effectively delivers vaccine payloads to antigen presenting cells (APC) and allows easy-to-manufacture vaccine candidates
.
It has been shown in animal models and cancer patients.
Powerful CD8+ antigen-specific T cell response
.
Combining their platform with our industry-leading VelociSuite technology and expertise may help accelerate this emerging and promising treatment method
.
"Reference: 1.
https: //
.
According to the terms of this cooperation, Nykode Therapeutics will be responsible for the production and characterization of the vaccine, as well as the product supply before the end of the phase 1 trial
.
Regeneron will be responsible for antigen identification, preclinical and clinical development and manufacturing, and commercialization
.
The agreement includes five different projects, three in the field of cancer and two in the field of infectious diseases
.
These vaccines will combine Regeneron's unique antigen selection expertise, proprietary VelociSuite technology and Nykode Therapeutics' modular vaccine platform
.
Nykode Therapeutics Nykode Therapeutics is a leading clinical stage biopharmaceutical company
.
Nykode Therapeutics is committed to discovering and developing vaccines and new immunotherapies for the treatment of cancer and infectious diseases
.
The core of Nykode Therapeutics' proprietary modular Vaccibody technology is to induce rapid, strong and lasting specific immune responses by targeting antigens to antigen-presenting cells
.
▲ Image source: Nykode Therapeutics official website The Vaccibody molecule consists of three functional modules: a targeting module that binds to the surface receptors of antigen presenting cells, a dimerization module, and an antigen module derived from pathogenic factors
.
The genes of each module are genetically related and encode a new type of fusion protein called the Vaccibody protein
.
The platform can be used to encode a series of different targeting modules and antigen modules to provide fuel for a variety of new products
.
The selected targeting module determines the delivery of the antigen to a specific subpopulation of APC or cell type, which ultimately affects the kinetics and immune response profile
.
So far, clinical Vaccibody vaccines have used a needleless jet syringe to deliver plasmids as DNA plasmids to muscle cells
.
Inside the cell, the DNA plasmid provides information to produce the Vaccibody protein in the same way that the cell produces other human proteins
.
Then the newly encoded Vaccibody protein is secreted from the cell and targets and recruits APC
.
Depending on the selection of the targeting module, different APCs subgroups will be targeted, which means that the immune response may be biased towards body fluids (antibodies) or cells (T cells) or their variants (CD8/CD4, Th1/Th2/Th17/ Treg)
.
▲ Mechanism of action of the Vaccibody platform (picture source: Nykode Therapeutics official website) Off-the-shelf cancer and infectious disease vaccines provide a fast, scalable and attractive method for cancer treatment
.
This vaccine targets shared antigens that are found in pathogens or expressed by tumors in a large population of patients
.
Nykode has accumulated rich experience in ready-made vaccines, including its infectious disease plan and the VB10.
16 clinical plan for HPV16-driven cancer types
.
In order to expand the clinical pipeline, Nykode will focus part of its research efforts on identifying shared cancer antigens and developing other off-the-shelf vaccines with future potential such as cancer, infectious diseases, and autoimmune diseases
.
Nykode Therapeutics' pioneering vaccine: ➤ VB10.
16VB10.
16 is a therapeutic vaccine for the treatment of malignant tumors induced by human papillomavirus 16
.
It is currently in a phase 2 trial for the treatment of cervical cancer
.
➤ VB10.
NEO cancer neoantigen vaccine VB10.
NEO is one of Nykode's main product candidates
.
It is currently in a Phase 1b trial for the treatment of locally advanced and metastatic tumors and a Phase 1/2a trial for the treatment of melanoma, lung cancer, head and neck cancer, kidney cancer and bladder cancer
.
➤ COVID-19 vaccine In 2021, Nykode launched two phase 1/2 trials of next-generation COVID-19 vaccine candidates
.
Michael Engsig, CEO of Nykode Therapeutics, said: "We are very pleased to reach this groundbreaking agreement with Regeneron, which may accelerate the expansion of our product line and take full advantage of our uniqueness in multiple large and commercially important disease areas.
The modular vaccine technology platform
.
This agreement further validates Nykode Therapeutics’s position as a leading next-generation immunotherapy platform company
.
We are excited about the choice of options and their therapeutic potential in cancer, as well as the potential for prevention and treatment of infectious diseases
.
"RegeneronRegeneron is a leading biotechnology company that invents and researches potential new drugs for a variety of serious diseases, including retinal eye disease, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases
.
Regeneron is working through it.
Proprietary VelociSuite technology accelerates and improves the traditional drug development process
.
▲ Image source: Regeneron official website ➤ VelociGeneVelociGene can quickly, automatically and large-scale manipulate mouse DNA, with almost no restrictions on the size and complexity of modifications
.
This makes it possible to validate therapeutic targets The speed and ability to point and create animal models of human diseases has reached unprecedented speed and ability
.
➤ VelociMouseVelociMouse is a breakthrough technology that can directly generate transgenic mice directly from modified embryonic stem cells, thereby avoiding the need for multiple generations of reproduction
.
this technology greatly reduces engineering time transgenic mice, while reducing costs, improving the accuracy
.
➤ VelocImmuneVelocImmune is a unique technology to produce fully human monoclonal antibodies
.
VelocImmune from immunized mice and efficient direct, directly create A large number of optimized antibody drug candidates
.
This method overcomes the limitations of traditional platforms by quickly creating fully human antibodies that are tightly bound to the therapeutic target, and avoiding potential immunity that may occur in patients receiving antibodies containing non-human components Response
.
➤ VelociMabVelociMab is a set of technologies that allows us to enter clinical research from identifying therapeutic antibodies at an unprecedented speed
.
VelociMab can perform high-throughput screening of potential therapeutic antibodies and quickly generate recombinant human antibody cell lines
.
Gavin Thurston, Senior Vice President of Oncology Research at Regeneron, said: "Nykode Therapeutics' platform effectively delivers vaccine payloads to antigen presenting cells (APC) and allows easy-to-manufacture vaccine candidates
.
It has been shown in animal models and cancer patients.
Powerful CD8+ antigen-specific T cell response
.
Combining their platform with our industry-leading VelociSuite technology and expertise may help accelerate this emerging and promising treatment method
.
"Reference: 1.
https: //
